Clinical trials: Platinum Refractory Epithelial Ovarian Cancer
Breast Cancer Female, Ovarian Cancer
Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients
Safety and tolerability of combination of Nivolumab and Ipilimumab will be studied in patients with 3 different types of cancers in 3 parts of the study, as shown below: Part 1 - Neoadjuvant Therapy of Breast Cancer; Part 2 …
- Conditions
- Breast Cancer Female, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03342417
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- ExcellaBio LLC
Ovarian Cancer, Endometrial Cancer
Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
The purpose of the study is to determine if the combination of Everolimus and Letrozole is effective in the treatment of women with either recurrent or persistent epithelial ovarian, fallopian tube, primary peritoneal or…
- Trial name
- NCT02188550
- Testing
- everolimus and letrozole
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sinai Hospital of Baltimore
Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
This phase I/II trial studies the side effects and best dose of veliparib and topotecan hydrochloride and to see how well they work in treating patients with solid tumors, ovarian cancer that has come back or does not respond to…
- Conditions
- Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01012817
- Testing
- Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study
- Where
- 15 sites in United States
- Volunteers
- 88 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Neoplasms
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
The purpose of this study is to determine if participants with platinum-refractory or platinum-resistant advanced ovarian cancer have a better outcome when treated with Olaratumab (IMC-3G3) in combination with Liposomal…
- Trial name
- NCT00913835
- Testing
- Olaratumab, liposomal doxorubicin
- Where
- 6 sites in United States
- Volunteers
- 125 people
- Sponsor
- Eli Lilly and Company
Fallopian Tube Cancer, Ovarian Cancer
Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT01402271
- Testing
- carboplatin, paclitaxel, pazopanib hydrochloride
- Where
- 9 sites in Belgium, Netherlands and 1 more
- Volunteers
- 88 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with…
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT05281471
- Testing
- olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
- Where
- 33 sites in United States
- Volunteers
- 186 people
- Sponsor
- Genelux Corporation
Platinum-Resistant Primary Peritoneal Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer
Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer
This is a phase-3, open-label, multicenter, two-arm treatment study to evaluate the efficacy and safety of weekly Paclitaxel Lipid Suspension compared with weekly conventional paclitaxel in participants with…
- Conditions
- Platinum-Resistant Primary Peritoneal Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer, Platinum Resistant High Grade Serous Ovarian Cancer
- Trial name
- NCT06867562
- Testing
- Paclitaxel Lipid Suspension, Conventional paclitaxel or Taxol
- Volunteers
- 166 people
- Sponsor
- Jina Pharmaceuticals Inc.
Solid Tumor, Solid Tumor, Adult
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of…
- Conditions
- Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor
- Trial name
- NCT06264921
- Testing
- NKT3447
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- NiKang Therapeutics, Inc.
Ovarian Neoplasms
Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer
The purpose of this research study is to determine if Telcyta® given in combination with liposomal doxorubicin is more effective than liposomal doxorubicin alone in treating women who have recurrent ovarian epithelial cancer…
- Trial name
- ASSIST-5 (NCT00350948)
- Testing
- Telcyta, Liposomal Doxorubicin
- Where
- 71 sites in United States, Belgium and 2 more
- Volunteers
- 244 people
- Sponsor
- Telik
Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
This is an open-label, phase 1/1b, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal…
- Conditions
- Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma
- Trial name
- PROTA (NCT05271318)
- Testing
- TILT-123, pembrolizumab, pegylated liposomal doxorubicin
- Where
- 3 sites in United States, Finland
- Volunteers
- 29 people
- Sponsor
- TILT Biotherapeutics Ltd.
Ovarian Cancer
Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer
Study of Pazopanib and weekly Paclitaxel in patients with platinum resistant/refractory ovarian cancer who relapse during bevacizumab maintenance.
- Trial name
- TAPAZ (NCT02383251)
- Testing
- Pazopanib, Paclitaxel
- Where
- 36 sites in France
- Volunteers
- 118 people
- Sponsor
- ARCAGY/ GINECO GROUP
Ovarian Cancer, Cancer of the Fallopian Tube
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy
Although initially responsive to cytoreductive surgery and platinum- and/or taxane-based chemotherapy, a majority of patients with epithelial ovarian cancer, cancer of the fallopian tube or the peritoneum will eventually relapse.
- Conditions
- Ovarian Cancer, Cancer of the Fallopian Tube, Peritoneal Cancer
- Trial name
- NCT00189358
- Testing
- ZD1839, tamoxifen
- Where
- Germany
- Sponsor
- AGO Study Group
Ovarian Neoplasms
TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer
The purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer, fallopian tube…
- Trial name
- NCT00102973
- Testing
- TLK286 in Combination with Carboplatin, Doxorubicin HCl Liposome Injection
- Where
- 222 sites in United States
- Volunteers
- 244 people
- Sponsor
- Telik
Advanced Solid Tumors, HR+ Breast Cancer
(VELA) Study of BLU-222 in Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.
- Conditions
- Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer
- Trial name
- NCT05252416
- Testing
- BLU-222, Carboplatin, Ribociclib
- Where
- 23 sites in United States, Italy and 1 more
- Volunteers
- 50 people
- Sponsor
- Blueprint Medicines Corporation
Ovarian Epithelial Cancer, Fallopian Tube Cancer
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
This is a Phase 1, open-label, dose-escalation ,and multidose study, aiming to investigate the safety, tolerability and pharmacokinetics of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary…
- Conditions
- Ovarian Epithelial Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04029909
- Testing
- Gimatecan 0.6mg/m2/d, 0.8mg/m2/d, 0.4mg/m2/d
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Lee's Pharmaceutical Limited
Platinum Refractory Epithelial Ovarian Cancer, Primary Cancer of the Peritoneum
Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor
Ovarian cancer is most often recognized in advanced clinical state, the initial therapeutic strategies consist of a platinum containing chemotherapy subsequent to primary surgery.
- Conditions
- Platinum Refractory Epithelial Ovarian Cancer, Primary Cancer of the Peritoneum, Cancer of the Fallopian Tube
- Trial name
- NCT00543049
- Testing
- Sunitinib
- Where
- 16 sites in Germany
- Volunteers
- 73 people
- Sponsor
- AGO Study Group
Ovarian Cancer, Peritoneal Cavity Cancer
Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00030706
- Testing
- ixabepilone
- Where
- United States
- Sponsor
- Montefiore Medical Center
Ovarian Cancer
MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)
This study will determine whether MK-4827 can be safely administered in combination with pegylated liposomal doxorubicin, and if so, will obtain an estimate of the benefit of the combination in patients with ovarian cancer as…
- Trial name
- NCT01227941
- Testing
- MK-4827 + pegylated liposomal doxorubicin
- Volunteers
- 6 people
- Sponsor
- Tesaro, Inc.
Ovarian Cancer
A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed
This is an open-label, single-arm, two-stage, multicenter Phase II study evaluating the efficacy and safety of bevacizumab in women with platinum resistant, advanced (Stage III or IV) EOC (epithelial ovarian cancer) or PPC…
- Trial name
- NCT00097019
- Testing
- bevacizumab
- Volunteers
- 53 people
- Sponsor
- Genentech, Inc.
Ovarian Cancer, Peritoneal Cavity Cancer
Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00436644
- Testing
- Lapatinib, Topotecan
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic